《九价人乳头瘤病毒疫苗临床应用指南：韩国妇科肿瘤学会指南》
Clinical guideline for 9-valent HPV vaccine: Korean Society of Gynecologic Oncology Guideline.
机构信息
Department of Obstetrics and Gynecology, Korea University Medical Center, Korea University College of Medicine, Seoul, Korea.
Department of Obstetrics and Gynecology, Keimyung University School of Medicine, Daegu, Korea.
出版信息
J Gynecol Oncol. 2019 Mar;30(2):e31. doi: 10.3802/jgo.2019.30.e31. Epub 2019 Jan 9.
Abstract
In 2016, 9-valent human papillomavirus (HPV) vaccine has been newly introduced in Korea, thus the need to develop recommendations for the vaccine has raised. Until we decide to develop a guideline, no further studies on the bi-valent or quadri-valent HPV vaccine have been announced. We searched and reviewed the literatures focused on the efficacy of 9-valent HPV vaccine, the ideal age of 3-dose schedule vaccination, the efficacy of 9-valent HPV vaccine in middle-aged women, the efficacy of the 2-dose schedule vaccination, the safety of 9-valent HPV vaccine, the possibility of additional 9-valent HPV vaccination, and cross-vaccination of 9-valent HPV vaccine. So, Korean Society of Gynecologic Oncology (KSGO) developed a guideline only for 9-valent HPV vaccine.
摘要
2016 年，九价人乳头瘤病毒（HPV）疫苗在韩国新引入，因此需要制定疫苗接种建议。在我们决定制定指南之前，尚未公布关于二价或四价 HPV 疫苗的进一步研究。我们搜索并回顾了九价 HPV 疫苗的功效、三剂接种方案的理想年龄、九价 HPV 疫苗在中年女性中的功效、两剂接种方案的功效、九价 HPV 疫苗的安全性、追加九价 HPV 疫苗接种的可能性以及九价 HPV 疫苗的交叉接种等方面的文献。因此，韩国妇科肿瘤学会（KSGO）仅为九价 HPV 疫苗制定了指南。
相似文献
1
Clinical guideline for 9-valent HPV vaccine: Korean Society of Gynecologic Oncology Guideline.《九价人乳头瘤病毒疫苗临床应用指南：韩国妇科肿瘤学会指南》
J Gynecol Oncol. 2019 Mar;30(2):e31. doi: 10.3802/jgo.2019.30.e31. Epub 2019 Jan 9.
2
Preventive vaccination against cervical cancer: Korean Society of Gynecologic Oncology Guideline.宫颈癌预防性疫苗接种：韩国妇科肿瘤学会指南
J Gynecol Oncol. 2016 May;27(3):e30. doi: 10.3802/jgo.2016.27.e30.
3
Updated clinical guideline for human papillomavirus vaccine: the Korean Society of Gynecologic Oncology guidelines.人乳头瘤病毒疫苗更新临床指南：韩国妇科肿瘤学会指南。
J Gynecol Oncol. 2021 Nov;32(6):e94. doi: 10.3802/jgo.2021.32.e94.
4
Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).四价人乳头瘤病毒疫苗：免疫实践咨询委员会（ACIP）的建议
MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24.
5
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.24至45岁女性四价人乳头瘤病毒（6、11、16、18型）重组疫苗的安全性、免疫原性及有效性：一项随机双盲试验
Lancet. 2009 Jun 6;373(9679):1949-57. doi: 10.1016/S0140-6736(09)60691-7. Epub 2009 Jun 1.
6
Clinical perspectives on the role of the human papillomavirus vaccine in the prevention of cancer.关于人乳头瘤病毒疫苗在癌症预防中的作用的临床观点。
Pharmacotherapy. 2011 Mar;31(3):280-97. doi: 10.1592/phco.31.3.280.
7
Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.智利女性人乳头瘤病毒疫苗的健康经济分析：基于马尔可夫模型的医疗保健支付方视角
BMC Public Health. 2014 Nov 26;14:1222. doi: 10.1186/1471-2458-14-1222.
8
US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines.美国对癌症中HPV类型的评估：对当前和九价HPV疫苗的影响。
J Natl Cancer Inst. 2015 Apr 29;107(6):djv086. doi: 10.1093/jnci/djv086. Print 2015 Jun.
9
The introduction of the human papillomavirus vaccine - key issues.人乳头瘤病毒疫苗的引入——关键问题
Br J Nurs. 2009;18(2):86-9. doi: 10.12968/bjon.2009.18.2.37860.
10
[Cytology and DNA HPV-testing in the era of HPV-vaccine].[人乳头瘤病毒疫苗时代的细胞学与DNA人乳头瘤病毒检测]
Ginekol Pol. 2007 Sep;78(9):696-700.
引用本文的文献
1
Updated clinical guideline for human papillomavirus vaccine: the Korean Society of Gynecologic Oncology guidelines.人乳头瘤病毒疫苗更新临床指南：韩国妇科肿瘤学会指南。
J Gynecol Oncol. 2021 Nov;32(6):e94. doi: 10.3802/jgo.2021.32.e94.
2
Time for enhancing government-led primary prevention of cervical cancer.加强政府主导的宫颈癌一级预防刻不容缓。
J Gynecol Oncol. 2021 Jan;32(1):e12. doi: 10.3802/jgo.2021.32.e12. Epub 2020 Dec 11.
3
Prevalence and genotype distribution of genital human papillomavirus infection in female sex workers in the world: a systematic review and meta-analysis.全球女性性工作者中生殖器人乳头瘤病毒感染的患病率及基因型分布：一项系统评价与荟萃分析
BMC Public Health. 2020 Sep 25;20(1):1455. doi: 10.1186/s12889-020-09570-z.
4
The 61st Annual Meeting of the Japanese Society for Gynecologic Oncology (JSGO).日本妇科肿瘤学会（JSGO）第61届年会
J Gynecol Oncol. 2019 Nov;30(6):e114. doi: 10.3802/jgo.2019.30.e114.
本文引用的文献
1
Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women.二剂程序在女童和男童中与三剂程序在女性中比较的 9 价 HPV 疫苗免疫原性。
JAMA. 2016 Dec 13;316(22):2411-2421. doi: 10.1001/jama.2016.17615.
2
Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical Trials.9价人乳头瘤病毒疫苗的安全性概况：7项III期临床试验的综合分析
Pediatrics. 2016 Aug;138(2). doi: 10.1542/peds.2015-4387. Epub 2016 Jul 15.
3
A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men.一项比较九价和四价人乳头瘤病毒疫苗在男性中的免疫原性和安全性的III期临床研究。
Vaccine. 2016 Jul 29;34(35):4205-4212. doi: 10.1016/j.vaccine.2016.06.056. Epub 2016 Jun 25.
4
Preventive vaccination against cervical cancer: Korean Society of Gynecologic Oncology Guideline.宫颈癌预防性疫苗接种：韩国妇科肿瘤学会指南
J Gynecol Oncol. 2016 May;27(3):e30. doi: 10.3802/jgo.2016.27.e30.
5
Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine.9价人乳头瘤病毒疫苗在既往接种过4价人乳头瘤病毒疫苗的12至26岁女性中的安全性和免疫原性。
Vaccine. 2015 Nov 27;33(48):6855-64. doi: 10.1016/j.vaccine.2015.08.059. Epub 2015 Sep 26.
6
Coadministration of a 9-Valent Human Papillomavirus Vaccine With Meningococcal and Tdap Vaccines.九价人乳头瘤病毒疫苗与脑膜炎球菌和 Tdap 联合疫苗的使用。
Pediatrics. 2015 Sep;136(3):e563-72. doi: 10.1542/peds.2014-4199. Epub 2015 Aug 3.
7
Immunogenicity and safety of the 9-valent HPV vaccine in men.九价人乳头瘤病毒疫苗在男性中的免疫原性和安全性。
Vaccine. 2015 Nov 27;33(48):6892-901. doi: 10.1016/j.vaccine.2015.06.088. Epub 2015 Jul 2.
8
Immunogenicity and Safety of a 9-Valent HPV Vaccine.九价人乳头瘤病毒疫苗的免疫原性和安全性
Pediatrics. 2015 Jul;136(1):e28-39. doi: 10.1542/peds.2014-3745.
9
A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls.一项针对9至15岁女孩的9价人乳头瘤病毒L1病毒样颗粒疫苗（V503）与加德西疫苗®免疫原性和安全性的随机、双盲、III期研究
Pediatr Infect Dis J. 2015 Sep;34(9):992-8. doi: 10.1097/INF.0000000000000773.
10
Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine.II期研究以选择一种多价人乳头瘤病毒1型病毒样颗粒（VLP）疫苗的配方。
Hum Vaccin Immunother. 2015;11(6):1313-22. doi: 10.1080/21645515.2015.1012010.
Zotero 插件